Advanced Therapeutics in Parkinson and Movement Disorders
Episode 62, Apr 22, 2022, 10:00 AM
Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Yasar Torres-Yaghi, MD, director, Parkinsonism and Dementia Clinic, assistant professor of neurology, MedStar Georgetown University Hosptial, about the current state of therapeutic intervention for movement disorders, and this year's first annual Advanced Therapeutics in Movement & Related Disorders™ Congress, being put on by the PMD Alliance.
Click here to register and find more information on the ATMRD Congress.
In this episode, we spoke with Yasar Torres-Yaghi, MD, director, Parkinsonism and Dementia Clinic, assistant professor of neurology, MedStar Georgetown University Hosptial, about the current state of therapeutic intervention for movement disorders, and this year's first annual Advanced Therapeutics in Movement & Related Disorders™ Congress, being put on by the PMD Alliance.
Click here to register and find more information on the ATMRD Congress.
Episode Breakdown:
- 3:15 – Background on the new ATMRD Congress.
- 6:20 – Rates of adoption of novel therapeutics for Parkinson disease.
- 9:35 – What attendees should expect from the Congress this year.
- 11:20 – The need for a multidisciplinary approach to movement disorders and the multidisciplinary features of the Congress.
- 12:35 – Neurology News Minute
- 16:30 – Education and understanding about the optimal utilization of advanced therapies in Parkinson disease.
- 19:10 – Ongoing trends and conversations in the movement disorder field.
- 21:30 – Closing thoughts.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Approves Boston Scientific’s STIMVIEW XT Guided Imaging Software for DBS
- FDA Extends Review of Vutrisiran for ATTR Amyloidosis 3 Months, Now Expected in July 2022
- Higher-dose Erenumab Shows Better Prevention of Progression, Rationale Provided for Initiation at High Dose
Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.